Our Pricing

How to Safely Switch From Wegovy to Mounjaro in the UK: Cost Comparison and Clinical Guidance

Many patients considering switching from Wegovy to Mounjaro UK want to understand both the clinical transition process and the monthly cost implications. As a UK-registered pharmacy with thousands of weight loss patients under care, we've guided numerous individuals through this medication switch safely and effectively. This comprehensive guide covers everything you need to know about transitioning from semaglutide to tirzepatide, including washout periods, dosing protocols, and transparent UK pricing.

Understanding the Clinical Difference When Switching From Wegovy to Mounjaro UK

When switching from Wegovy to Mounjaro UK, you're transitioning from a single-hormone GLP-1 receptor agonist (semaglutide) to a dual-action GIP/GLP-1 receptor agonist (tirzepatide). This distinction matters clinically because tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors, potentially offering enhanced weight loss outcomes compared to semaglutide alone[1].

In the SURPASS-2 head-to-head trial comparing tirzepatide directly against semaglutide 1mg, patients on the highest tirzepatide dose (15mg) achieved an average weight loss of 12.4kg compared to 6.2kg with semaglutide over 40 weeks[2]. While individual results vary and are subject to prescriber assessment, this dual-receptor mechanism explains why many UK patients and clinicians consider switching from Wegovy to Mounjaro when seeking optimised weight management outcomes.

Both medications work by slowing gastric emptying, reducing appetite, and improving glycaemic control, but the additional GIP pathway activation in Mounjaro may enhance fat metabolism and insulin sensitivity. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) regularly advises patients that switching from Wegovy to Mounjaro UK should always be done under medical supervision, with proper dose titration to minimise side effects whilst maximising therapeutic benefit.

Safe Transition Protocol for Switching From Wegovy to Mounjaro UK

The process of switching from Wegovy to Mounjaro UK requires careful consideration of washout periods and dose equivalence. Semaglutide has a half-life of approximately one week, meaning it takes around 4-5 weeks to fully clear your system[3]. However, most UK prescribers don't require a complete washout period when transitioning between these medications, as both are GLP-1 receptor agonists with similar safety profiles.

The recommended approach when switching from Wegovy to Mounjaro UK involves stopping your current Wegovy dose and starting Mounjaro at the initial 2.5mg dose within one week. This conservative starting dose applies regardless of your Wegovy dose level, as Mounjaro's dual-receptor action means dose equivalence isn't direct. The 2.5mg starter dose minimises gastrointestinal side effects whilst your body adjusts to the new medication mechanism[4].

Your UK prescriber will create a personalised titration schedule, typically increasing Mounjaro by 2.5mg increments every four weeks until reaching your optimal maintenance dose (usually 5mg, 7.5mg, 10mg, 12.5mg, or 15mg). This gradual escalation when switching from Wegovy to Mounjaro UK significantly reduces the risk of nausea, vomiting, and other common side effects that can occur with too-rapid dose increases.

Timing Your Injection Schedule During the Switch

Both Wegovy and Mounjaro are once-weekly injections, which simplifies the transition timeline when switching from Wegovy to Mounjaro UK. Most patients find it easiest to maintain their existing injection day (for example, if you inject Wegovy every Monday, continue with Mounjaro on Mondays). Administer your first Mounjaro dose on your next scheduled injection day after stopping Wegovy, typically within 7 days of your last semaglutide injection. This approach maintains consistent therapeutic coverage whilst avoiding medication overlap that could increase side effect risk.

Monthly Cost Comparison When Switching From Wegovy to Mounjaro UK

Understanding the financial implications is essential when switching from Wegovy to Mounjaro UK. At Cured Pharmacy, Mounjaro is available from £124.99 per month, with an additional £20 off your first order using code Weightlossnew, bringing your initial month to £124.99. This transparent upfront pricing includes your medication, UK prescriber consultation, and discreet home delivery.

Wegovy pricing at Cured Pharmacy starts from £124.99 per month, making it initially less expensive than Mounjaro. However, when evaluating the monthly cost of switching from Wegovy to Mounjaro UK, many patients consider the enhanced efficacy data from clinical trials. The SURPASS-2 trial demonstrated that tirzepatide 15mg achieved nearly double the weight loss of semaglutide 1mg over 40 weeks[2], which some patients find justifies the price difference when seeking maximum weight loss results.

The actual monthly cost when switching from Wegovy to Mounjaro UK depends on your prescribed maintenance dose. Lower Mounjaro doses (2.5mg or 5mg) may be priced differently than higher doses (10mg, 12.5mg, or 15mg), and your UK prescriber will determine the appropriate dose based on your weight loss goals, tolerance, and medical history. All pricing at Cured Pharmacy is shown before your consultation, ensuring complete transparency with no hidden fees.

Expected Outcomes and Timeline After Switching From Wegovy to Mounjaro UK

Patients switching from Wegovy to Mounjaro UK often ask about expected weight loss timelines and whether they'll experience additional results. Clinical evidence suggests that individuals who plateau on semaglutide may achieve further weight reduction after transitioning to tirzepatide, though individual responses vary significantly and depend on numerous factors including diet, exercise, starting BMI, and metabolic health[1].

In clinical trials, maximum weight loss with Mounjaro typically occurred around 72 weeks of treatment, with the highest dose (15mg) producing average total body weight reductions of up to 22.5% in some studies[5]. When switching from Wegovy to Mounjaro UK, you shouldn't expect immediate dramatic changes during the initial titration phase (first 3-4 months), as you'll be gradually increasing doses. Most patients notice enhanced appetite suppression and renewed weight loss momentum once reaching their optimal maintenance dose.

It's important to maintain realistic expectations when switching from Wegovy to Mounjaro UK. While clinical trials show superior average outcomes with tirzepatide, not every patient will experience additional weight loss, and some may respond equally well to either medication. Your UK prescriber will monitor your progress through regular follow-ups and adjust your treatment plan accordingly, potentially optimising dose or recommending complementary lifestyle interventions to maximise results.

Managing Side Effects During the Transition

Even when switching from Wegovy to Mounjaro UK after tolerating semaglutide well, you may experience gastrointestinal side effects during the transition. Common effects include nausea, diarrhoea, constipation, and reduced appetite, typically most pronounced during dose escalation phases. Starting at the 2.5mg Mounjaro dose and increasing gradually every four weeks allows your body to adapt to the dual GIP/GLP-1 mechanism whilst minimising discomfort. Practical strategies include eating smaller meals, avoiding high-fat foods, staying well-hydrated, and timing your injection consistently each week. Most side effects diminish within 4-8 weeks as your body adjusts to each new dose level.

Who Should Consider Switching From Wegovy to Mounjaro UK

Switching from Wegovy to Mounjaro UK may be appropriate for several patient groups, though the decision must always involve consultation with a UK prescriber. Patients who've plateaued on maximum-dose Wegovy (2.4mg semaglutide weekly) but haven't yet reached their target weight often consider transitioning to tirzepatide for its potentially superior efficacy. Similarly, individuals who experienced good initial results with Wegovy but have seen weight loss slow or stop after 6-12 months may benefit from the dual-receptor mechanism of Mounjaro[6].

Some patients consider switching from Wegovy to Mounjaro UK due to tolerability issues rather than efficacy concerns. While both medications share similar side effect profiles, individual responses vary, and some people find they tolerate tirzepatide's gastrointestinal effects better than semaglutide's, or vice versa. Additionally, patients with type 2 diabetes seeking both glycaemic control and weight management may prefer Mounjaro based on its dual-action mechanism and robust HbA1c reduction data from the SURPASS trial programme.

Conversely, switching from Wegovy to Mounjaro UK isn't appropriate for everyone. Patients achieving excellent results on Wegovy with minimal side effects and reaching their weight goals may have no clinical reason to switch. Cost-conscious individuals may prefer to continue with the lower-priced semaglutide option. Your UK prescriber will assess your individual circumstances, including current weight loss trajectory, side effect profile, medical history, and treatment goals, to determine whether transitioning medications is clinically justified in your specific case.

How to Access Mounjaro After Switching From Wegovy to Mounjaro UK Through Cured Pharmacy

Accessing Mounjaro when switching from Wegovy to Mounjaro UK through Cured Pharmacy involves a straightforward online consultation process. All prescription weight loss medications require clinical assessment by a UK-registered prescriber, which we provide through our secure online platform. The consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any previous experience with GLP-1 medications like Wegovy.

After submitting your consultation for switching from Wegovy to Mounjaro UK, our clinical team (overseen by superintendent pharmacist Tarun Kumar, GPhC 2233073) reviews your information within hours. If Mounjaro is deemed clinically appropriate and safe for you, a UK prescriber will issue your prescription, and we'll dispense genuine UK-licensed tirzepatide from our GPhC-registered pharmacy (9012511). Your medication arrives in 100% discreet packaging via next-day delivery, with all pricing transparent before you begin the consultation.

We provide ongoing clinical support throughout your treatment journey when switching from Wegovy to Mounjaro UK. Monthly follow-up consultations ensure your dose remains optimised, side effects are managed effectively, and your weight loss progress stays on track. You can contact our pharmacy team at (+44) 116 4646009 with any questions about your medication, injection technique, or treatment plan. Our commitment to lowest UK prices means you'll receive competitive pricing on all doses, with your first order eligible for £20 off using code Weightlossnew.

What to Expect During Your Online Consultation

The online consultation for switching from Wegovy to Mounjaro UK asks detailed questions about your current Wegovy dose, how long you've been taking it, your weight loss results to date, and any side effects experienced. Be prepared to share your current weight, height, target weight, and relevant medical conditions including cardiovascular disease, pancreatitis history, thyroid disorders, or diabetic retinopathy. The prescriber needs to know all medications you're currently taking, as some may interact with GLP-1 receptor agonists. Honest, complete answers ensure safe prescribing and optimal treatment outcomes. Most consultations are approved within 24 hours, allowing you to begin your Mounjaro treatment quickly and safely under proper medical supervision.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Wegovy (semaglutide) Summary of Product Characteristics. (2023). Electronic Medicines Compendium. Novo Nordisk Ltd. [accessed 15 August 2026]
4. Mounjaro (tirzepatide) Summary of Product Characteristics. (2023). Electronic Medicines Compendium. Eli Lilly and Company Limited. [accessed 15 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
6. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE guidance. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.